UK clinical-stage biotech PureTech Health (LSE: PRTC) announced that it has sold 1 million shares of its founded entity, Karuna Therapeutics (Nasdaq: KRTX), through a block trade executed by Morgan Stanley & Co for cash consideration of around $118 million.
Karuna’s shares edged up 2.2% to $118.00 in pre-market trading this morning, while PureTech was virtually unchanged.
PureTech intends to use the proceeds from the transaction to further expand and advance its clinical-stage wholly-owned pipeline. PureTech intends to update financial guidance in connection with the issuance of its 2020 Annual Report and Accounts later this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze